Adhera Therapeutics Inc (ATRX)

[Jose Chavez]

$ATRX In its research, Melior discovered the unexpected benefits of MLR-1019 for PD, subsequently securing the intellectual property (“IP”) with several patents. Based upon Melior’s work, a clear understanding of MLR-1019’s mechanism of action, abundant pre-clinical research and decades of clinical data on mesocarb, which is chemically related to armesocarb, Melior and Adhera believe that MLR-1019 represents a significant opportunity to address a large gap in therapeutics for PD. Specifically, it is theorized that MLR-1019 can potentiate the anti-Parkinsonian activity of levodopa (L-DOPA), a drug commonly prescribed for controlling movement symptoms of Parkinson’s and mitigate the L-DOPA-induced dyskinesia (PD-LID) associated with L-DOPA therapy more effectively than amantadine and without the unpleasant adverse events.